Supernus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Operational Context Achieved record 2025 revenues of $719 million, successfully transitioning the business model following the loss of exclusivity for legacy products Trokendi XR and Oxtellar XR. Growth was primarily driven by a 40% revenue increase across four key products: Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO, which now represent 76% of total revenues. Successfully integrated the Sage Therapeutics acqui ...

Core Viewpoint - Biogen is set to report its fourth-quarter and full-year 2025 results on February 6, with expectations for sales of $2.21 billion and earnings per share of $1.60, following a previous quarter where earnings exceeded expectations by 23.65% [1][10]. Sales Performance - Sales of Biogen's multiple sclerosis (MS) drugs are anticipated to decline due to generic competition for Tecfidera and biosimilar competition for Tysabri, although new products may offset some of this decline [2]. - The Zacks Consensus Estimate for Tecfidera sales is $120 million, while Tysabri is estimated at $362 million, and Vumerity is expected to rise to $183 million due to increased demand [3]. - U.S. MS sales were better than expected in the first three quarters of 2025, driven by Vumerity, but a steeper decline is expected in the fourth quarter due to increased competition, particularly in Europe [4]. Drug-Specific Insights - Sales of Spinraza are projected to decline to $380 million due to lower demand, while Skyclarys is expected to show sequential growth supported by demand and geographic expansion [5]. - Zurzuvae is likely to continue rising in sales, benefiting from strong patient demand and an expanding prescriber base, with its approval in the EU contributing to growth [6][7]. - Alzheimer's collaboration revenues are expected to rise, driven by Biogen's share of net product revenues from Leqembi, which has shown sequential sales improvement in the U.S. [8][9]. Earnings Surprise and Stock Performance - Biogen has a history of beating earnings estimates, with a four-quarter average surprise of 14.02%, and its stock has increased by 25.9% over the past year, outperforming the industry average of 15.2% [12][13]. - The company's Earnings ESP is currently -2.49%, indicating that the model does not predict an earnings beat this time [15][16].

Group 1 - Aristotle Capital Boston, LLC reported strong performance in small-cap equities, with the Russell 2000 Index reaching an all-time high since November 2021, driven by a favorable macroeconomic environment [1] - The Small Cap Equity Fund (Class I-2) returned 3.16% in Q3 2025, underperforming the Russell 2000 Index's total return of 12.39% [1] - The fund highlighted Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) as a key stock, which saw a one-month return of 8.74% and a 52-week gain of 39.09% [2] Group 2 - Supernus Pharmaceuticals, Inc. is a Maryland-based specialty pharmaceutical company focused on central nervous system diseases, reporting strong quarterly results that exceeded analyst expectations and raised fiscal year 2025 forecasts [3] - The company reported total revenue of $192.1 million in Q3 2025, an increase from $175.7 million in Q3 2024 [4] - Despite its potential, Supernus Pharmaceuticals is not among the top 30 most popular stocks among hedge funds, with 29 hedge fund portfolios holding its stock at the end of Q3 2025, up from 25 in the previous quarter [4]

Core Insights - Armistice Capital sold 2,152,000 shares of Travere Therapeutics, reducing its position by approximately $29.3 million in the third quarter [2][7] - Following the sale, Armistice holds 6.7 million shares valued at $160.7 million, representing 2% of its assets under management (AUM) [3][4] - Travere Therapeutics' stock price increased by 100% over the past year, significantly outperforming the S&P 500, which rose nearly 14% in the same period [4] Company Overview - Travere Therapeutics has a market capitalization of $3.2 billion and reported a revenue of $435.8 million for the trailing twelve months (TTM) [5] - The company incurred a net loss of $88.5 million in the TTM [5] - As of the latest market close, Travere's share price was $35.44 [5] Business Focus - Travere Therapeutics specializes in therapies for rare diseases, with marketed products including Chenodal, Cholbam, and Thiola, and is advancing clinical candidates like Sparsentan and TVT-058 [6][9] - The company targets high unmet medical needs in the biotechnology sector, leveraging clinical expertise and strategic partnerships for growth [9] Recent Performance - Travere Therapeutics reported a strong quarter with total revenue reaching $164.9 million, driven by a 155% year-over-year increase in FILSPARI's U.S. sales [10] - The company achieved a GAAP net income of $25.7 million, a significant turnaround from a $54.8 million loss a year earlier [10] Investment Perspective - Despite the sale of shares, Armistice Capital remains heavily invested in Travere, which still accounts for 5% of its AUM and is its second-largest holding [11] - The sale appears to be a disciplined portfolio management decision following a significant share price rebound rather than a change in investment thesis, especially with an upcoming FDA decision in FSGS [11] - Long-term investors may find Travere appealing due to its accelerating commercial uptake, improving profitability, and upcoming regulatory catalysts [12]

Core Insights - Third Avenue Small-Cap Value Fund reported a return of 7.18% in Q3 2025, underperforming the MSCI USA Small-Cap Value Index at 8.97% and the Russell 2000 Value Index at 12.60% [1] - The fund's performance was positively influenced by a diverse range of businesses, with Supernus Pharmaceuticals, Inc. being the largest contributor [3] Company Performance - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) experienced a one-month return of -4.85% but saw a significant 29.42% increase in value over the past 52 weeks, closing at $47.11 per share with a market capitalization of $2.691 billion on November 5, 2025 [2] - The company is benefiting from a strong financial position, current profitability, an expanding neurology drug portfolio, and effective capital allocation, which facilitated a successful acquisition during the quarter [3] Hedge Fund Interest - Supernus Pharmaceuticals, Inc. was held by 25 hedge fund portfolios at the end of Q2 2025, a slight decrease from 26 in the previous quarter, indicating a stable but cautious interest among hedge funds [4]

Investment Rating - The industry investment rating is "Outperform" (maintained) [1] Core Viewpoints - The potential of the antidepressant market is enormous, with over 350 million people affected globally, including more than 90 million in China. The global antidepressant market is projected to reach approximately $17.11 billion by 2024, growing at a compound annual growth rate (CAGR) of 4.2% to $17.82 billion by 2025 [3][12][21] - There is a significant unmet need for effective antidepressant medications, as existing treatments have limitations in efficacy and safety. The development of new antidepressants should focus on balancing "rapid onset" and "long-term safety" [3][21] - The report highlights the advancements in drug development, with overseas companies leading the way, while domestic companies like Kanghong Pharmaceutical, Warner Pharmaceuticals, and Xinlitai are also making progress [3][22][24] Summary by Sections Antidepressant Market Overview - The global burden of depression is substantial, with 350 million cases worldwide and 90 million in China. The lifetime prevalence of depression in Chinese adults is 6.8% [12][21] - The antidepressant market is expected to grow steadily, reaching $20.25 billion by 2029 [12][21] Drug Development Trends - Traditional antidepressants, such as SSRIs, take 2-4 weeks to show effects, while newer GABA/glutamate-based drugs can provide rapid relief within hours. This has led to a focus on optimizing drug structures and formulations [3][24] - New generation antidepressants are being developed with a focus on "monoamine deepening + multi-mechanism combination" strategies [3][21] Key Companies and Products - The report suggests monitoring companies with promising pipelines, including Kanghong Pharmaceutical, Warner Pharmaceuticals, Xinlitai, and Jibeier [3][22][24] - Specific products highlighted include: - Esketamine (Spravato) for treatment-resistant depression, which has shown rapid effects [28] - Auvelity, a combination of dextromethorphan and bupropion, which has demonstrated quick onset of action [36] - Zuranolone, a GABA-A receptor modulator, approved for postpartum depression, showing rapid efficacy [40][43] - JJH201501 from Jibeier, which has shown significant efficacy and safety advantages over traditional treatments [47]

Core Insights - The biotech sector is experiencing significant momentum, with many clinical-stage and commercial biopharma stocks reaching new 52-week highs due to breakthrough trial data, strategic deals, and earnings surprises [1] Company Summaries - **Metsera Inc. (MTSR)**: A clinical-stage biopharmaceutical company focused on developing hormone analog peptides for obesity and related metabolic diseases. Recently, Novo Nordisk made a $9 billion unsolicited acquisition proposal, which Metsera's board considers superior to its existing agreement with Pfizer [2][3]. Metsera announced positive Phase 2b results for its GLP-1 receptor agonist MET-097i, showing up to 14.1% weight loss after 28 weeks, supporting Phase 3 initiation in late 2025 [4]. The stock rose from $32.35 to a 52-week high of $66.10, a gain of 104.3% [5]. - **Indivior Plc (INDV)**: Develops buprenorphine-based therapies for opioid dependence. The company reported Q3 net income of $42 million, up from $22 million a year ago, with adjusted earnings of $93 million, exceeding Wall Street's expectations [6][7]. The stock increased from $20.86 to a 52-week high of $30.55, reflecting a 46.5% gain [7]. - **Insmed Inc. (INSM)**: Focused on therapies for serious and rare diseases, Insmed reported a Q3 net loss of $370 million but saw net product revenue rise to $142.3 million from $93.4 million last year [8][9]. The company raised its full-year 2025 revenue guidance for ARIKAYCE to $420 million - $430 million, indicating 15% - 18% growth year-over-year [10]. The stock surged from $76.54 to a 52-week high of $194.70, marking a 154.4% gain [10]. - **Ventyx Biosciences Inc. (VTYX)**: A clinical-stage biotech company developing therapies for autoimmune and neurodegenerative diseases. Ventyx reported positive Phase 2 results for its NLRP3 inhibitor VTX3232, showing strong safety and tolerability [11][13]. The stock rose from $3.01 to a 52-week high of $8.52, a gain of over 183% [14]. - **Inhibrx Biosciences Inc. (INBX)**: Focuses on oncology and rare diseases, announcing positive topline results from its ChonDRAgon study for ozekibart in chondrosarcoma [15]. The stock increased from $18.35 to a 52-week high of $83.78, representing a gain of 356.6% [16]. - **ABIVAX Société Anonyme (ABVX)**: Developing therapies for chronic inflammatory diseases, ABIVAX presented positive Phase 3 data for obefazimod in ulcerative colitis [17]. The stock rose from $7.83 to an all-time high of $106.73, marking a significant gain of 1263% [18]. - **Arrowhead Pharmaceuticals Inc. (ARWR)**: Developing RNAi-based therapies, Arrowhead finalized a licensing agreement with Novartis for ARO-SNCA, with financial terms including a $200 million upfront payment [19][20][21]. The stock increased from $29.70 to a 52-week high of $43.33, representing a gain of over 45% [21]. - **Kodiak Sciences Inc. (KOD)**: Focused on retinal diseases, Kodiak announced positive Phase 1b data for KSI-101, showing significant vision improvements [22][23][24]. The stock climbed from $8.98 to a 52-week high of $21.17, delivering a 135.7% gain [22]. - **Arcutis Biotherapeutics Inc. (ARQT)**: Focused on dermatological treatments, Arcutis reported Q3 net income of $7.4 million, a turnaround from a net loss last year, with revenue up 122% year-over-year [25][26]. The stock rose from $14.99 to a 52-week high of $27.08, representing a gain of over 80% [27]. - **Maze Therapeutics Inc. (MAZE)**: Developing precision therapies for various diseases, Maze announced positive Phase 1 results for MZE782 and secured $150 million in a private placement [28][29]. The stock rose from $11.21 to a new 52-week high of $34.29, returning a gain of 206% [29]. - **Supernus Pharmaceuticals Inc. (SUPN)**: Focused on CNS disorders, Supernus is expected to report Q3 earnings of $0.82 per share and revenue of $180.22 million [30][31]. The stock increased from $38.21 to a 52-week high of $57.65, representing a gain of over 50% [31].

Core Insights - Biogen reported Q3 2025 adjusted EPS of $4.81, exceeding the Zacks Consensus Estimate of $3.89, with an 18% year-over-year increase [1][11] - Total revenues for the quarter reached $2.53 billion, a 3% increase year-over-year, driven by strong sales growth of new drugs [2][11] Financial Performance - Product sales amounted to $1.85 billion, up 4% year-over-year, with anti-CD20 therapeutic program revenues rising 11% to $494 million [3][11] - Contract manufacturing and royalty revenues fell 35% year-over-year to $151 million, while Alzheimer's collaboration revenues increased to $43 million from $19 million [4][5] Drug Sales and Growth - Biogen's MS revenues totaled $1.06 billion, a 1% increase on a reported basis, with Vumerity sales up 36% year-over-year to nearly $215 million [7][11] - Tecfidera sales declined 28% to $168 million, while Tysabri sales rose 6% to $432 million [8][11] - Rare disease drug Skyclarys generated $133 million in sales, a 30% increase year-over-year [12][11] Cost Management - Adjusted R&D expenses decreased 7% year-over-year to $432 million, while adjusted SG&A expenses rose 6% to $592 million [16][11] Guidance and Future Outlook - Biogen raised its sales guidance for 2025, expecting approximately flat or 1% growth in constant currency terms [17][11] - Adjusted EPS guidance was lowered from $15.50-$16.00 to $14.50-$15.00 due to anticipated costs from business development transactions [19][11] Strategic Developments - Biogen resubmitted a regulatory filing for a higher dose of Spinraza, with a decision expected by April 3, 2026 [20][21] - The company completed enrollment in late-stage studies for litifilimab, with data readouts expected in the second half of 2026 [22][11] Market Position - Despite competitive pressures on MS drugs and Spinraza, Biogen's new products are positioned to drive long-term growth [27][11] - The company aims to build a multi-franchise portfolio with significant revenue potential from key pipeline products [27][11]

Core Viewpoint - Amphastar Pharmaceuticals (AMPH) is expected to report a year-over-year decline in earnings due to lower revenues for the quarter ended September 2025, with the consensus outlook indicating a potential impact on stock price based on actual results compared to estimates [1][2]. Financial Expectations - The consensus estimate for Amphastar's quarterly earnings is $0.77 per share, reflecting a year-over-year decrease of 19.8%. Revenues are anticipated to be $184.53 million, down 3.5% from the same quarter last year [3]. - Over the last 30 days, the consensus EPS estimate has been revised 1.71% higher, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Amphastar is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -4.55%, indicating a bearish outlook from analysts [12]. - The stock currently holds a Zacks Rank of 3, making it challenging to predict a beat on the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Amphastar exceeded the expected earnings of $0.71 per share by delivering $0.85, resulting in a surprise of +19.72%. Over the past four quarters, the company has beaten consensus EPS estimates twice [13][14]. Industry Comparison - Another company in the Zacks Medical - Generic Drugs industry, Supernus Pharmaceuticals (SUPN), is expected to report earnings of $0.47 per share for the same quarter, indicating a year-over-year decline of 55.7%. Revenues are projected to be $182.06 million, up 3.6% from the previous year [18]. - The consensus EPS estimate for Supernus has been revised 14.3% higher in the last 30 days, but its Earnings ESP is 0.00%, combined with a Zacks Rank of 1, making it difficult to predict a beat on the consensus EPS estimate [19][20].

Core Insights - BridgeBio Pharma reported a quarterly loss of $0.95 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.88, marking an earnings surprise of -7.95% [1] - The company generated revenues of $120.7 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 14.44%, compared to revenues of $2.73 million in the same quarter last year [2] - The stock has increased by approximately 135.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 17.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.76 on revenues of $134.92 million, and for the current fiscal year, it is -$3.47 on revenues of $467.46 million [7] - The estimate revisions trend for BridgeBio Pharma was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Generic Drugs industry, to which BridgeBio Pharma belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]